HIV Drug Resistance - PAHO/WHO | Pan American Health …
Sep 21, 2023 · HIV drug resistance (HIVDR) is the ability of HIV to mutate and reproduce in the presence of antiretroviral (ARV) drugs. The consequences of drug resistance include treatment failure; the transmission of drug resistant HIV; as well as increased direct and indirect costs, for patients and health systems, due to more expensive, complex and toxic second- and third-line …
Concept note: Surveillance of HIV drug resistance in adults ... - PAHO
Jul 7, 2014 · HIV Drug Resistance emerges when HIV replicates in the presence of antiretroviral drugs. If HIV drug resistance becomes widespread, the drugs currently used to treat HIV infection may become ineffective. To date, levels of HIV Drug Resistance in countries scaling up ART remain manageable. However, resistance is slowly increasing: in East Africa, resistance rates …
HIV/AIDS - PAHO/WHO | Pan American Health Organization
Sep 30, 2024 · ART reduces mortality and morbidity rates among HIV-infected people, and improves their quality of life. The benefits of ART also include the prevention of HIV transmission by suppressing HIV replication in persons living with the virus. This benefit of ART is also defined as “undetectable equal untransmittable” , or U=U.
New HIV infections, deaths and persons living with HIV receiving ART in Latin America and the Caribbean ...
Guidelines for managing advanced HIV disease and rapid ... - PAHO
Jul 7, 2017 · Rapid initiation of ART is defined as within seven days of HIV diagnosis. WHO further strongly recommends ART initiation on the same day as HIV diagnosis based on the person’s willingness and readiness to start ART immediately, unless there are clinical reasons to delay treatment.
Paediatric Abacavir/Lamivudine/Dolutegravir (pALD) Fixed-Dose
Jun 6, 2023 · Dolutegravir (DTG)-based HIV treatment regimens are recommended by the World Health Organization (WHO) for children living with HIV (CLHIV) who weigh at least 3 kg. In 2020, the United States Food and Drug Administration (US FDA) granted tentative approval of paediatric DTG 10 mg scored, dispersible tablets (pDTG) for CLHIV weighing a minimum ...
PAHO highlights countries' progress, challenges in expanding …
Jun 27, 2012 · The series of fact sheets released this week provide data on the HIV epidemic in 32 countries and territories of the Americas. Details are provided on HIV prevalence, the percentage of HIV patients on ART, public spending on ART, HIV mortality, HIV-tuberculosis co-infections, and other key aspects of the epidemic.
Pre-Exposure Prophylaxis (PrEP) - PAHO/WHO | Pan American …
Dec 5, 2023 · Pre-exposure prophylaxis (PrEP) is a HIV medication that when used consistently, reduces the risk of HIV infection during sex by over 90%. WHO PrEP guidelines currently recommends the use of PrEP taken daily for both men and women who are at substantial risk of acquiring HIV. Daily PrEP use provides the highest amount of medication in the blood and …
Updated recommendations on first-line and second-line ... - PAHO
Dec 21, 2018 · Update on early infant diagnosis of HIV: Since 2010, WHO has been recommending that HIV virological testing be used to diagnose HIV infection among infants and children younger than 18 months and that ART be started without delay while a second specimen is collected to confirm the initial positive virological test result. Since that time ...
Combination HIV Prevention - PAHO/WHO | Pan American Health …
Sep 12, 2022 · UNAIDS defines combination HIV prevention as rights-, evidence-, and community-based programs that promote a combination of biomedical, behavioral, and structural interventions designed to meet the HIV prevention needs of specific people and communities. Its goal is to reduce the number of new infections through activities with a greater ...